Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38973065.
- Also identified by DOI 10.1093/infdis/jiae213 and PMC identifier 11646606.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.
Medical subject headings
- Ritonavir
- SARS-CoV-2
- Hydroxylamines
- Antiviral Agents
- Drug Resistance, Viral
- Cytidine
- Mutation
- COVID-19 Drug Treatment
- Leucine